MAMMALIAN EMBRYONIC HEMATOPOIESIS
Embryonic development of the mammalian hematopoietic system is spatially and temporally complex. Two major sources of hematopoietic activity have been described in mammalian embryos. Early studies defined hematopoietic activity within the yolk sac (YS) as the initial site where primary and definitive hematopoietic precursor cells were formed (1) . Intraembryonic hematopoietic activity observed in avian, amphibian, and murine embryos indicated additional hematopoietic sites (2, 3) . In amphibian embryos, the dorsal lateral plate mesoderm contributes to definitive hematopoiesis, whereas the ventral blood island, which is equivalent to the YS, contributes to both primitive and definitive hematopoiesis (4) .
Similar sites of definitive hematopoietic activity can be identified in the mouse embryo prior to definitive hematopoiesis in the liver (5) (6) (7) (8) . The visceral para-aortic splanchonopleura (P-Sp) region contains multipotent lymphomyeloid progenitors, although they are unable to reconstitute adult recipients (9) (10) (11) . During organogenesis, part of the splanchnopleura transforms into a morphologically distinct composite axial structure consisting of the dorsal aorta, genital ridges, and mesonephri (AGM) region. Spleen colony-forming units are concentrated in the AGM region and umbilical vessels at late 10/early 11 days postcoitum (d.p.c.) (6, 7) . By 11 d.p.c., hematopoietic stem cells (HSCs) appear both in the liver rudiment and the YS, but only the cells from AGM region are able to expand into HSCs in organ culture conditions (8) . These observations led to the hypothesis that the AGM region is the site of formation of definitive HSCs, which then colonize secondary hematopoietic organs, primarily the fetal liver (12, 13) . It is unclear whether primary hematopoietic cells from theYS contribute to the hematopoiesis in the AGM, since as early as day 7 p.c., before circulation is established in the mouse embryo, the P-Sp but not the YS contains ancestors of the cells that are capable of long-term, multipotential repopulation of adult irradiated recipients (10, 11) . Also upon transplantation into nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice, cultured dorsal aorta cells showed lymphomyeloid reconstitution, whereas YS cells were only capable of contributing to the myeloid lineage (10, 11) .
In contrast to the studies described above, other models suggest that independent production or expansion of definitive hematopoietic cells may occur in the YS. Although early YS cells are unable to repopulate adult irradiated recipients upon direct transplantation, when transplanted into newborn recipients, they can contribute to adult hematopoiesis (14) (15) (16) . In addition, by day 8 p.c. both the P-Sp and the YS contain cells that can mature into definitive HSC by co-culture with an AGM-derived stromal cell line (17) . Thus, at least from day 8 p.c., the YS contains "predefinitive HSCs" that are capable of development into definitive HSC upon maturation in an embryonic or newborn microenviroment (18) . To quantify the hematopoietic activities from both sites, an organ culture approach was used to allow specific examination of HSC activity within isolated tissues (19 (22) .
IN VITRO MODELS FOR STUDIES OF MOUSE HEMATOPOIESIS
Embryonic stem (ES) cell-based developmental models provide many advantages for studies of embryologic events in vitro. ES cells provide a large population of homogeneous cells that can be readily manipulated to better understand the extracellular stimuli and intracellular processes that regulate lineage-specific development. Hematopoiesis has been particularly amenable to studies using mouse ES cells. As described in this review, recent work suggests that human ES cells also provide a valuable developmental model system ( Figure 1) .
Murine ES cells grown in suspension culture without feeder cells or leukemia inhibitory factor (LIF) spontaneously form cell aggregates called embryoid bodies (EBs). The EBs form cystic structures that resemble YS, including regions of blood islands. Indeed, hematopoietic development as defined by surface antigen expression and gene expression in EBs occurs in a temporal fashion similar to that found in the mouse embryo (23) . However, until recently, studies of hematopoietic development in the EBs have largely failed to demonstrate the presence of authentic HSCs that can reconstitute adult recipients in a long-term multilineage manner.
Hematopoietic development of mouse ES cells has also been studied via co-culture with adherent stromal cell lines derived from hematopoietic microenvironments. The OP9 stromal cell line, established from newborn calvaria of op/op mice, has been commonly used to support mouse hematopoiesis. The op/op mouse shows osteopetrosis caused by the deficiency of osteoclasts (24, 25) .
The primary defect of the mutant mouse is a mutation in the coding region of macrophage colony-stimulating factor gene. Differentiation of ES cells by the OP9 system is similar to the EB formation method. After LIF is removed, ES cells are co-cultured on OP9 cells. After approximately 5 days, the ES cells begin to differentiate into mesodermal colonies. Multipotential hematopoietic colonies begin to appear after reseeding these primary cells onto new OP9 cells. After about 14 days, hematopoietic cells continue to proliferate and differentiate to produce erythrocytes, macrophages, granulocytes, megakaryocytes, and B-lineage cells.
Comparison of EB and stromal cell-mediated hematopoietic differentiation of mouse ES cells identifies some differences between these two models. For example, the OP9 system seems more amenable to development of lymphoid cells (B cells) than the EB-based method (26) . These B cells generated in vitro from ES cells are functionally analogous to normal fetal liver-derived or bone marrow-derived B-lineage cells. FLK-1 deficient (FLK-1 -/-) ES cells further divide the two methods. Genetic studies in mice demonstrate an intrinsic requirement for the vascular endothelial growth factor (VEGF) receptor, FLK-1, in the early development of both the hematopoietic and endothelial cell lineages (27, 28) . FLK-1 -/-ES cells were examined for their hematopoietic potential in vitro during EB formation or when cultured on the stromal cell line OP9. In EB cultures, FLK-1 -/-ES cells were able to differentiate into all myeloid-erythroid lineages (27) . In contrast, although FLK-1 -/-ES cells formed mesodermal-like colonies on OP9 monolayers, they failed to generate hematopoietic clusters even in the presence of exogenous cytokines (29) .
MOLECULAR MECHANISMS OF HEMATOPOIETIC DEVELOPMENT
The ability to use homologous recombination to delete specific genes of interest in mouse ES cells provides a powerful means for precise genetic and developmental analysis of spe- 
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cific cell lineages. Murine hematopoiesis has been very amenable to this type of analysis. For example, FLK-1 is known to play a key role in the regulation of embryonic vascular and hematopoietic development (30) . In the mouse embryo, FLK-1 expression can be detected in mesodermal YS blood island progenitors as early as 7.0 d.p.c. Mice deficient in FLK-1 do not develop blood vessels or YS blood islands and die between 8.5 and 9.5 d.p.c. (28, 30) . In chimeric aggregation studies with wild-type embryos, FLK-1 -/-ES cells fail to participate in vessel formation or to contribute to primitive or definitive hematopoiesis in vivo (31) . These studies suggest that FLK-1 is crucial for development of a common endothelial/hematopoietic precursor, putative hemangioblast cells. Blast colony-forming cells (BL-CFCs) are thought to represent mouse ES cell-derived hemangioblasts (28, 32) . In response to VEGF, BL-CFCs form colonies containing FLK-1 expressing blast cells that give rise to primitive and definitive hematopoietic and endothelial cells in vitro (28, 32) . The mechanism of FLK-1 to promote hemangioblast formation is unclear. FLK-1 -/-BL-CFCs appear to develop normally within FLK-1 -/-EBs, but fail to respond to VEGF in forming blast colonies. Consequently, the number of blast colonies is greatly reduced (28) . Nevertheless, FLK-1 -/-blast cells retain the potential to differentiate into hematopoietic and endothelial cells in culture (28) . It is likely that the role of FLK-1 may not be for generation of hematopoietic-endothelial progenitors, but rather for the subsequent expansion and migration of such cells.
The FLK-1 + cells express the transcription factor GATA-1 prior to the expression of endothelial or hematopoietic lineage markers (33) (34) (35) . The FLK-1 + GATA-1 + cells represent a transient population. Primitive erythroid progenitors isolated from mouse ES cells are exclusively in the FLK-1 + GATA-1 + and FLK-1 -GATA-1 + fractions (36) . These findings suggest that the differentiation from FLK-1 + mesodermal cells to GATA-1 + progeny correlates with primitive hematopoiesis in the extraembryonic mesoderm. In addition to primitive erythropoiesis, the initial wave of definitive hematopoietic progenitors, predominantly consisting of definitive erythroid and macrophage progenitors, were detected exclusively in the FLK-1 + GATA-1 + fraction. The appearance of definitive hematopoietic progenitors together with primitive erythroid progenitors suggest that the first wave hematopoiesis arising from the FLK-1 + mesoderm is the combination of primitive erythroid and definitive hematopoietic differentiation. This observation is further supported by the appearance of definitive erythroid and macrophage progenitors within the YS at a stage of primitive erythropoiesis prior to the establishment of circulation in mouse embryos (37) . The identification of definitive erythroid and macrophage progenitors, together with primitive erythroid progenitors, suggests common hematopoietic precursors for primitive and definitive lineages arise from the FLK-1 + mesoderm.
While a subset of FLK-1 + mesodermal cells gave rise to GATA-1 + progeny, the majority of FLK-1 + cells differentiated without GATA-1 expression and did not exhibit hematopoietic progenitor activity (36) . This finding suggests that the GATA-1 -progeny of the FLK-1 + mesoderm do not possess the capacity to give rise to primitive erythropoiesis and the initial wave of definitive hematopoiesis. However, the FLK-1 + GATA-1 -fraction can give rise to VE-cadherin + cells, a surface antigen functional on endothelial cells (36, 38, 39) . In an ES cell in vitro differentiation system, VE-cadherin + cells give rise to VE-cadherin + FLK-1 + CD31 + sheet-like structures, which incorporate acetylated low-density lipoprotein (ac-LDL), confirming their endothelial identity (34, 35) . Divergence between the primitive erythroid and endothelial lineages occurs at the stage when a subset of the FLK-1 + mesoderm begins to express GATA-1. Shortly after the divergence of primitive erythroid and initial wave of definitive hematopoietic lineages, the second wave of definitive hematopoietic progenitors could be detected in VE-cadherin + cells. The VE-cadherin + progenitors showed a multipotential ability for generating definitive erythroid, myeloid, and lymphoid lineages, indicating that these cells represent progenitors of a definitive hematopoietic lineage encompassing multiple types of blood cells (36) . These findings demonstrate definitive hematopoietic potential is present in a subset of VE-cadherin + cells. The purified VE-cadherin + cells have been shown to generate endothelial cells in vitro (36) . These observations support the idea VE-cadherin + represent "hemangioblast" or "hemogenic endothelial" cells that retain the potential to form both lineages.
The TAL1/SCL basic helix-loop-helix (bHLH) transcription factor is likely a downstream element of FLK-1 signaling in hemangioblast cells. TAL1 expression was detected in the presumptive YS region in the mid/late-streak stage of mouse embryos (40, 41) , coincident with FLK-1, and continues to be expressed in hematopoietic cells in later stages (42) . Studies in zebrafish and mice both suggest TAL1 expression is very similar to that of FLK-1 and may mark hemangioblasts (43) . Overexpression of TAL1 in the fish resulted in an increase of both blood cells and blood vessels (43) . Also, studies of mouse ES cell-derived EBs demonstrate TAL1 expression initiates shortly after FLK-1 (44) . Cells that are positive for both FLK-1 and TAL1 expression are enriched for hemangioblasts, as assessed by the BL-CFC assay (32, 43) . TAL1 is also expressed in low levels on angioblasts and endothelial cells (41, 45) . Furthermore, FLK-1 -/-ES cell-derived mesodermal cells are unable to differentiate into hematopoietic precursors on OP9 cells and do not express TAL1, in contrast to wild-type ES cell-derived mesodermal cells (29) . Gene targeting experiments confirmed that TAL1 is essential for the development of all hematopoietic cells (46) . The recent inducible system by Cre recombination on a genetic background of TAL1 knock-out suggested that SCL is likely required around day 3.5-4.5 (47) . Considering that the first FLK-1 + cells and VE-cadherin + cells appear at days 3.0 and 5.0, respectively, the probable interpretation of this time course is that TAL1 is required during the FLK-1 + VE-cadherin -mesodermal stage. The induction of TAL1 later than day 4.0 could not restore the competence to differentiate to hematopoietic precursor cells (HPCs). Hence, mesodermal cells that failed to express TAL1/SCL appear to be irreversibly excluded from HPC fate.
Orkin and colleagues have demonstrated that upon differentiation of wild-type and SCL-deficient EBs, CD41 (GpIIb) was the earliest surface marker missing from SCL -/-EBs (48). Although commonly referred to as the megakaryocytespecific marker during adult hematopoiesis, these results sug-
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gest CD41 + cells derived from wild-type EBs can give rise to various definitive colony types, including mixed colonies. The absence of CD41 expression and hematopoietic activity in SCL -/-EBs suggests that CD41 is a possible useful marker for early hematopoietic development. Since the endothelial cell markers endoglin (CD105), CD31, and MECA32 appear in EBs approximately 1 day earlier than CD41, the endothelial cell lineage most likely develops before the development of CD41 + cells (48) . The adherent cells expressing FLK-1 and CD31 develop from the CD41 -fraction within EBs (48) . All these suggest that CD41 expression divides the hemangioblast cell population into hemogenic and nonhemogenic components. Mitjavila-Garcia et al. also observed that most YS and AGM hematopoietic progenitor cells were CD41 + , whereas only a minority of bone marrow and fetal liver hematopoietic progenitors expressed this antigen. In contrast, more than 90% of fetal liver and bone marrow progenitor cells were CD34 + (49) . All these results demonstrate that expression of CD41 is associated with early stages of hematopoiesis. Besides the possible significance of CD41 as a marker of the definitive hematopoietic lineage in the embryo, the functional role of CD41 during hematopoietic development is still unknown, because CD41 knock-out mice fail to demonstrate any striking abnormalities in hematopoiesis other than a platelet function defect (50) .
TRANSPLANTATION OF MOUSE ES CELL-DERIVED HEMATOPOIETIC CELLS
While hematopoiesis from mouse ES cells has been elegantly studied in tissue culture models, in vivo transplantation to achieve stable long-term multilineage hematopoietic engraftment of adult mice using differentiated mouse ES cells has been notoriously difficult to achieve, for reasons that remain largely unclear. One study did demonstrate limited lymphoid engraftment from EB-derived cell populations differentiated for 11-22 days in culture (51) . Another study demonstrated long-term hematopoietic engraftment from EB populations differentiated for only 4 days (52), although apparently this has been difficult to reproduce. There are several possible barriers that prevent successful transplantation in these models. It may be that the embryonic hematopoietic cells do not properly home to the bone marrow. That is, they do not effectively reach a requisite hematopoietic microenvironment. Alternatively, the adult microenvironment may fail to provide appropriate signals required to maintain embryonic hematopoietic cells that may have unique growth requirements.
Chronic myelogenous leukemia (CML) is a clonal malignancy of the pluripotent hematopoietic stem cell (53) . The Philadelphia chromosome that is pathognomonic for CML creates a chimeric fusion gene BCR/ABL, generating the oncogenic BCR/ABL protein (54, 55) . Expression of BCR/ABL in mouse ES cells allowed derivation of blood cells that could produce primitive erythroid colonies in vitro and definitive lymphoid and myeloid progeny in adult hosts (56) . Of course, these mice engrafted with BRC/ABL + ES cell-derived hematopoietic precursors succumbed to leukemia. However, this experiment suggested that ES cell-derived HSCs can grow and differentiate after injection into adult mice. Overexpression of BCR/ABL might have promoted engraftment by the combination of altering the homing properties of the donor cell, complementing a missing cytokine signal, or blocking apoptosis of the donor cell, providing it with time to acclimatize to the adult environment. It may also be possible that BCR/ABL promotes self-renewal properties of the embryonic hematopoietic cells.
Overexpression of HOXB4 in primitive hematopoietic progenitors from YS or differentiated ES cells, combined with culture on OP9 stroma, is also shown to promote the expansion of hematopoietic populations with definitive hematopoietic stem cell potential (57) . The cultured cells express several HSC markers, including c-kit, Sca-1, and CD31, and are rich in hematopoietic CFCs, particularly multipotent colony-forming unit granulocyte-erythrocyte-macrophagemegakaryocytes (CFU-GEMMs). Most importantly, they engraft and repopulate long-term lymphoid-myeloid hematopoiesis in irradiated primary and secondary recipients, thereby satisfying the functional definition of the definitive hematopoietic stem cell (58, 59) . This experiment also suggests that intermediate hematopoietic precursor cells are poised to become definitive HSCs. Since overexpression of HoxB4 in hematopoietic stem cells from bone marrow promotes significant self-renew and survival (57, 60, 61) , it is likely that similar mechanisms promote stable engraftment of ES cell-derived HSCs.
HUMAN ES CELLS TO STUDY HEMATOPOIESIS
While in many ways quite similar, there are key differences in embryonic development of mice and humans. For example, mouse embryos can be maintained in diapause, a state of suspended embryo growth prior to uterine implantation. Diapause requires LIF to be present in the uterine environment. However, human and nonhuman primate embryos do not have the capacity to undergo diapause and demonstrate a requirement for LIF to regulate embryogenesis. It is thought that this difference may account for the requirement of LIF or other agonists of the gp130/STAT3 signaling pathway to maintain undifferentiated growth of mouse ES cells, whereas LIF is not required to maintain human ES cells (62, 63) . More directly relevant to studies of hematopoiesis is the developmental biology of the YS, which is the site of the earliest stages of primitive hematopoiesis. Whereas the YS exists as a single structure during mouse embryogenesis, human embryos produce both a primary and a secondary YS (64, 65) . Therefore, lessons derived from studies of mouse ES cells may not always correspond to normal human development.
Initial studies to demonstrate the multilineage developmental potential of human ES cells used nonspecific methods to induce differentiation, such as teratoma formation or EB formation (66, 67) . This work demonstrated that human ES cells had the potential to derive hematopoietic tissue, although no specific conditions were described to support this development and no specific hematopoietic lineages were described.
Subsequent work to more specifically support hematopoietic differentiation of human ES cells used a co-culture system with stromal cells isolated from hematopoietic microenvironments to serve as "feeder" cells. S17 cells derived from mouse bone marrow, C166 cells derived from mouse YS, OP9 cells from mouse calvaria, and human bone marrow stroma have all been used to support hematopoiesis from human ES cell (68) . Here, human ES cells are taken out of the conditions that support their undifferentiated growth and instead co-cultured with one of the irradiated stromal cell lines in media containing fetal bovine serum (FBS) but no other specific cytokines or growth factors. The ES cells rapidly differentiate under these conditions. After 2 to 3 weeks, approximately 2%-5% of the differentiated cell population is CD34 + (undifferentiated human ES cells are CD34 -). When made into a single-cell suspension and cultured in a methylcellulose-based media containing requisite hematopoietic cytokines, these differentiated ES cells form stereotypical hematopoietic colonies that appear identical to those colonies derived from normal human bone marrow or umbilical cord blood. These CFCs represent well-characterized hematopoietic progenitors. Derivation and isolation of CFCs demonstrates that this culture system not only supports differentiation into mature terminally differentiated blood cells (such as erythrocytes, monocytes, or neutrophils), but earlier hematopoietic precursor cells can also be produced. As expected from studies other sources of human hematopoietic precursors (bone marrow and cord blood), enrichment of CD34 + cells derived from the human ES cells dramatically increases the yield of CFCs. Importantly, co-culture of the ES cells on fibroblasts (nonhematopoietic stromal cells) or in serum-free media does not lead to generation of CFCs. Therefore, efficient hematopoietic differentiation or maintenance of hematopoietic cells derived from human ES cells requires a combination of factors from both serum and stromal cells. Current efforts to better characterize these growth requirements are underway.
EBs can also be derived from human ES cells as a means to examine lineage-specific differentiation. As described above, EB formation has been a commonly used method to study hematopoietic differentiation of mouse ES cells. However, unlike mouse ES cells, human ES cells in a single-cell suspension fail to efficiently form EBs. Instead, to form EBs from human ES cells, intact colonies of cells cultured on mouse embryonic fibroblasts (MEFs) are digested by collagenase or dispase to form small cell clusters. These cell clusters are allowed to further aggregate in FBS-containing media (Chen et al., unpublished data) . EBs again resemble the early embryonic structure of the YS (Figure 2, A and B) . Sectioning of the EBs and subsequent immunolabeling by 
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CD34 antibody reveals the histological features of the YS. Both noncohesive hematopoietic precursor cells present in the lumen of endothelial lining are CD34 + . Primary hematopoietic precursor cells that mainly give rise to erythrocytes and megakaryocytes start to form at day 10 ( Figure 2, C and  D) . Definitive hematopoietic precursor cells that can give rise to macrophage and granulocyte colonies form at day 13-18, with the peak at day 14-16 ( Figure 2, E-H) . This activity represents the first wave of hematopoiesis formation, the combination of primary and definitive hematopoietic activity. Notably, the EB-mediated hematopoietic maturation time of human ES cells is approximately twice as long as mouse ES cell-derived EBs.
As described for stromal cell-mediated differentiation of human ES cells, EB-mediated hematopoiesis also requires FBS, and this has been long recognized in the mouse EB system. Additional growth factors such as thrombopoietin (TPO), vascular endothelial growth factor (VEGF), and bone morphogenetic protein 4 (BMP4) can also promote proliferation and hematopoietic activity of adult hematopoietic stem cells (69) . Chadwick et al. showed that BMP4, alone or in combination with other hematopoietic cytokines, was shown to significantly promote hematopoiesis (70) . Even though the mechanism is still unclear, it is likely that BMP4 and other cytokines promote hematopoiesis lineage differentiation or progenitor self-renew or both.
Cell surface antigen expression can be measured to evaluate the developmental stage and lineage of hematopoietic cells (Figure 3) . Interestingly, undifferentiated human ES cells express FLK-1 and the stem cell factor receptor c-kit (68) . FLK-1 and c-kit have increased expression after 6 days of EB formation and then start to gradually decrease. In contrast, VE-cadherin is not detected in undifferentiated human ES cells, but is seen in day 6 EBs and peaks at day 10. This time may represent a shift towards the definitive hematopoietic precursor phase, based on comparable studies from mouse ES cells (38) . Immediately after day 10, increased glycophorin A expression is seen, which correlates with the first wave of development of erythrocyte progenitors. Endothelial markers such as CD31, CD105, and CD146 start to be expressed at almost the same time. Other markers for hematopoietic cells, CD41 and CD45, emerge on day 12-16, again indicating a shift to definitive hematopoiesis. Together, these results demonstrate that the human EB system seems to recapitulate human embryogenesis. Whether the definitive hematopoietic cells, capable of long-term multilineage engraftment into adult recipients, can be derived from human ES cells, either by EB formation or stromal cell co-culture, remains unknown at this time.
FUTURE DIRECTIONS
The ability to grow human ES cells in essentially unlimited numbers in well-defined conditions makes these cells an ideal starting population to better define the phenotype and genotype of human HSCs. Numerous surrogate assays exist to characterize human HSCs in vitro (71) . However, the best method to demonstrate a prospective human cell population is capable of long-term multilineage engraftment in vivo uses transplantation immunodeficient mice (typically NOD/SCID or a related strain) (72) . The so-called SCID repopulating cells (SRCs) are most likely the closest phenotype to HSCs that can be defined in the human system, short of transplantation into clinical patients (73) . Typically, prospective human HSC populations are injected intravenously into immunodeficient mice, and blood or bone marrow is analyzed at appropriate intervals for presence of human blood cells (74, 75) . Identification of human-derived cells approximately 12 weeks postinjection is considered evidence of a long-term repopulating cell (SRC). Experiments to induce in vitro differentiation of human ES cells and then transplant the whole population or varying subpopulations (e.g., CD34 -versus CD34 + cells) into NOD/SCID mice will be the first step to identify human HSCs within this population. It remains to be determined whether many of these same hurdles described above regarding engraftment of mouse ES cell-derived HSCs will also prove to be barriers to stable transplantation of human ES cell-derived hematopoietic cells.
CONCLUSION
Research on human ES cells is in its infancy. Based on the considerable results obtained from studies of mouse ES cells over the past 20 years, human ES cells will profoundly impact our understanding of human developmental biology. Most likely, the impact of human ES cells will at least initially be more indirect. Whether (or when) human ES cell-based therapies can be directly applied to treat a host of currently incurable diseases brought on by degenerative, malignant, or otherwise damaging processes remains promising but speculative at this point. The ability to use human ES cells to analyze the earliest stages of hematopoiesis in a human system, however, should permit identification of genes and proteins that function to maintain HSCs capable of longterm engraftment. The ability to genetically modify human ES cells (76) (77) (78) also provides an important tool to decipher the mechanism of differentiation and oncogenesis. Together, these tools will help this field mature and lead to better understanding and treatment of a host of hematopoietic diseases.
